Radu Kramer
Nephrology · Paramus, NJNPI 1326036898
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,149 of the $11,299 with a category attached, or 63.3%. 38 manufacturers reported payments, led by Indivior Inc. at 27.6% of the total. Reporting peaked in 2019 at $3,973 and has fallen 82.5% since, to $693 in 2025. Among nephrology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 398 payments — averaging $28.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$3K
- AbbVie$3K
- Biohaven Pharmaceuticals, Inc.$1K
- Amgen$849
- Otsuka America Pharmaceutical, Inc.$466
- Takeda Pharmaceuticals U.S.A., Inc.$269
- plus $2K from 32 others
What the payments were for
- Consulting fees$1,20011%
- Speaking & faculty fees$1,95017%
- Travel & lodging$8688%
- Food & beverage$7,14963%
- Education$1321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,299 in reported general payments places this provider in the 90th percentile of 413 nephrology providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 66 | $73,239 |
| VraylarCariprazine Hcl | 19 | $35,406 |
| Invega SustennaPaliperidone Palmitate | 12 | $31,413 |
| LinzessLinaclotide | 31 | $21,741 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 19 | $13,383 |
| MyrbetriqMirabegron | 22 | $12,974 |
| EliquisApixaban | 20 | $12,913 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 30 | $8,656 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $7,698 |
| Lisdexamfetamine Dimesylate | 23 | $5,867 |
| OxycontinOxycodone Hcl | 11 | $5,052 |
| Testosterone | 18 | $4,715 |
| KlonopinClonazepam | 12 | $4,121 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,690 |
| Nebivolol Hcl | 36 | $1,772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Olanzapine | $197 | $73,64289 claims |
| AbbVieVraylar, Linzess | $3,096 | $57,14750 claims |
| Johnson & JohnsonInvega Sustenna | $196 | $31,41312 claims |
| Orexo US, Inc.Zubsolv | $14 | $13,38319 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $12,97422 claims |
| PfizerEliquis | $60 | $12,91320 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $269 | $7,69820 claims |
| AstraZenecaSymbicort | $24 | $2,69012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Paramus
- Mikhail KotlovParamus$6K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
- Jeffrey GoodmanFlorham Park$70K
- Arif AsifNeptune$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.